AXSOME THERAPEUTICS INC (AXSM)
US05464T1043 - Common Stock
We assign a fundamental rating of 2 out of 10 to AXSM. AXSM was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of AXSM is average, but there are quite some concerns on its profitability. While showing a medium growth rate, AXSM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AXSM has reported negative net income.
AXSM had a negative operating cash flow in the past year.
AXSM had negative earnings in each of the past 5 years.
AXSM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -40.67%, AXSM perfoms like the industry average, outperforming 48.72% of the companies in the same industry.
Looking at the Return On Equity, with a value of -125.27%, AXSM is doing worse than 65.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.67% | ||
| ROE | -125.27% | ||
| ROIC | N/A |
ROA(3y)-81.88%
ROA(5y)-66.39%
ROE(3y)-377.3%
ROE(5y)-252.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 90.37%, AXSM belongs to the top of the industry, outperforming 92.82% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AXSM has more shares outstanding
The number of shares outstanding for AXSM has been increased compared to 5 years ago.
The debt/assets ratio for AXSM is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.28 indicates that AXSM is not in any danger for bankruptcy at the moment.
AXSM has a Altman-Z score of 3.28. This is in the better half of the industry: AXSM outperforms 76.92% of its industry peers.
A Debt/Equity ratio of 0.93 indicates that AXSM is somewhat dependend on debt financing.
The Debt to Equity ratio of AXSM (0.93) is worse than 73.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.28 |
ROIC/WACCN/A
WACC9.24%
2.3 Liquidity
AXSM has a Current Ratio of 3.63. This indicates that AXSM is financially healthy and has no problem in meeting its short term obligations.
AXSM has a Current ratio of 3.63. This is comparable to the rest of the industry: AXSM outperforms 53.85% of its industry peers.
AXSM has a Quick Ratio of 3.52. This indicates that AXSM is financially healthy and has no problem in meeting its short term obligations.
AXSM has a Quick ratio (3.52) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.63 | ||
| Quick Ratio | 3.52 |
3. Growth
3.1 Past
AXSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.79%.
Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 440.77%.
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-47.52%
Revenue 1Y (TTM)440.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q193.52%
3.2 Future
Based on estimates for the next years, AXSM will show a very strong growth in Earnings Per Share. The EPS will grow by 35.80% on average per year.
AXSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.30% yearly.
EPS Next Y25.43%
EPS Next 2Y48.05%
EPS Next 3Y51.52%
EPS Next 5Y35.8%
Revenue Next Year41.52%
Revenue Next 2Y60.65%
Revenue Next 3Y60.47%
Revenue Next 5Y50.3%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AXSM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AXSM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AXSM's earnings are expected to grow with 51.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.05%
EPS Next 3Y51.52%
5. Dividend
5.1 Amount
No dividends for AXSM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AXSOME THERAPEUTICS INC
NASDAQ:AXSM (5/3/2024, 7:00:01 PM)
After market: 76 +1.2 (+1.6%)74.8
+0.61 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.55B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.67% | ||
| ROE | -125.27% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.37% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.63 | ||
| Quick Ratio | 3.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)440.77%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y